EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 112 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR A tribute to Dame Valerie Beral October 13, 2022 Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than... October 13, 2025 Female Representation at the Top of the Oncology Field Has Hit... October 20, 2021 HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 Load more HOT NEWS FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... Sex, intimacy and cancer – That Cancer Conversation Boosting Dendritic Cells Helps the Immune System Find Pancreatic Cancer Study Examines Whether Blood Test Can Identify Early Cancers
